Characterization of Pseudoxanthoma Elasticum
Characterization of Patients With Pseudoxanthoma Elasticum
1 other identifier
observational
100
1 country
1
Brief Summary
Pseudoxanthoma elasticum (PXE) is a rare multisystem disorder of autosomal recessive inheritance (OMIM# 264800) and an estimated prevalence between 1:25.000 and 1:100.000. PXE is characterized by calcification and fragmentation of connective tissue rich in elastic fibers. Due to its high content of elastic fibers, Bruch Membrane in eyes of patients affected by PXE becomes thickened and calcified. The ocular phenotype is characterized by angioid streaks and peau d'orange but also choroidal neovascularizations and chorioretinal atrophy thereby in part mimicking the phenotype of age-related macular degeneration. The disease is due to mutations of the ABCC6-gene coding for a transmembrane protein which is mainly expressed in the liver and kidney. It is hypothesized that ABCC6 is involved in the excretion of a yet unknown factor from the liver which inhibits systemic calcification. In animal models several candidates for this factor have been identified but direct evidence for such a factor in patients with PXE is still missing. The primary purpose of this study is to further investigate the ocular phenotype of patients with PXE using multimodal imaging and functional testing to delineate the impact of Bruch membrane pathology on the eye. Furthermore, possible systemic anti-calcification factors, as well as associations with the vascular alterations are investigated to gain more insights into the pathogenesis of PXE..
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 1, 2014
CompletedFirst Posted
Study publicly available on registry
April 9, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedJune 20, 2018
June 1, 2018
4.9 years
April 1, 2014
June 18, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ocular phenotype
Patients are investigated using a multimodal imaging approach and visual function testing.
patients will be followed longitudinally with an expected 1-year average interval between visits
Secondary Outcomes (1)
Biomarkers in PXE
1 day (first visit)
Eligibility Criteria
Pseudoxanthoma elasticum
You may qualify if:
- Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Ophthalmology, University of Bonn
Bonn, North Rhine-Westphalia, 53127, Germany
Related Publications (11)
Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet. 2013 Apr 4;4:14. doi: 10.3389/fgene.2013.00014. eCollection 2013.
PMID: 23577018BACKGROUNDFinger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HP, Holz FG, Lamoureux EL. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes. 2011 Dec 12;9:113. doi: 10.1186/1477-7525-9-113.
PMID: 22152229BACKGROUNDCharbel Issa P, Finger RP, Gotting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010 Jul;117(7):1406-14. doi: 10.1016/j.ophtha.2009.11.008. Epub 2010 Mar 1.
PMID: 20189652BACKGROUNDFinger RP, Charbel Issa P, Ladewig M, Gotting C, Holz FG, Scholl HP. Fundus autofluorescence in Pseudoxanthoma elasticum. Retina. 2009 Nov-Dec;29(10):1496-505. doi: 10.1097/IAE.0b013e3181aade47.
PMID: 19823106BACKGROUNDCharbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5913-8. doi: 10.1167/iovs.09-3541. Epub 2009 Jun 24.
PMID: 19553619BACKGROUNDGliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013 Jul-Aug;33(7):1300-14. doi: 10.1097/IAE.0b013e3182914d2b.
PMID: 23719398BACKGROUNDGliem M, Fimmers R, Muller PL, Brinkmann CK, Finger RP, Hendig D, Holz FG, Charbel Issa P. Choroidal changes associated with Bruch membrane pathology in pseudoxanthoma elasticum. Am J Ophthalmol. 2014 Jul;158(1):198-207.e3. doi: 10.1016/j.ajo.2014.04.005. Epub 2014 Apr 13.
PMID: 24727260BACKGROUNDCharbel Issa P, Gliem M, Holz FG, Knabbe C, Hendig D. [Pseudodominant inheritance of pseudoxanthoma elasticum]. Ophthalmologe. 2015 Aug;112(8):686-90. doi: 10.1007/s00347-014-3231-9. German.
PMID: 25735631BACKGROUNDGliem M, Hendig D, Finger RP, Holz FG, Charbel Issa P. Reticular pseudodrusen associated with a diseased bruch membrane in pseudoxanthoma elasticum. JAMA Ophthalmol. 2015 May;133(5):581-8. doi: 10.1001/jamaophthalmol.2015.117.
PMID: 25764262BACKGROUNDGliem M, Muller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P. Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3323-30. doi: 10.1167/iovs.16-19388.
PMID: 27367499BACKGROUNDGliem M, Muller PL, Birtel J, McGuinness MB, Finger RP, Herrmann P, Hendig D, Holz FG, Charbel Issa P. Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6159-6165. doi: 10.1167/iovs.17-22007.
PMID: 29214314BACKGROUND
Related Links
Biospecimen
whole blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Charbel Issa, MD
Department of Ophthalmology, University of Bonn
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
April 1, 2014
First Posted
April 9, 2014
Study Start
January 1, 2014
Primary Completion
December 1, 2018
Study Completion
December 1, 2018
Last Updated
June 20, 2018
Record last verified: 2018-06